Deutsche Bank Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating, Announces Price Target of $800
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst James Shin has initiated coverage on Regeneron Pharmaceuticals with a Hold rating and a price target of $800.
November 09, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals has been initiated with a Hold rating by Deutsche Bank, with a price target of $800.
The Hold rating from Deutsche Bank indicates a neutral outlook for Regeneron Pharmaceuticals. The price target of $800 suggests that the analyst believes the stock is fairly valued at this price. This could potentially lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100